Yazhen Wang

Yazhen Wang

Auto-generated profile, based on publicly available information

Yazhen Wang

National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610064, P. R. China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
LQLin Qin
Lin Qin
JCJun Cao
Jun Cao
KSKun Shao
Kun Shao
FTFan Tong
Fan Tong
ZYZhihang Yang
Zhihang Yang
NPNicholas A. Peppas
Nicholas A. Peppas
In situ vaccine–based combinatorial therapy induced potent tumor-specific immunity against tumor recurrence and metastasis.

21 June 2024 in Science Advances
Verified
Journal Article
Open access
YWYazhen Wang
Yazhen Wang
LYLianyi Yang
Lianyi Yang
CYChenxing Yan
Chenxing Yan
YDYufan Du
Yufan Du
TLTinghua Li
Tinghua Li
JCJun Cao
Jun Cao
Autophagy-targeting chimera (AUTAC) has emerged as a powerful modality that can selectively degrade tumor-related pathogenic proteins, but its low bioavailability and nonspecific distribution significantly restrict their therapeutic efficacy. Inspired by the guanine structure of AUTAC molecules, we here report supramolecular artificial Nano-AUTACs (GM NPs) engineered by AUTAC molecule GN [an indoleamine 2,3-dioxygenase (IDO) degrader] and nucleoside analog methotrexate (MTX) through supramolecular interactions for tumor-specific protein degradation. Their nanostructures allow for precise localization and delivery into cancer cells, where the intracellular acidic environment can disrupt the supramolecular interactions to release MTX for eradicating tumor cells, modulating tumor-associated macrophages, activating dendritic cells, and inducing autophagy. Specifically, the induced autophagy facilitates the released GN for degrading immunosuppressive IDO to further enhance effector T cell activity and inhibit tumor growth and metastasis. This study offers a unique strategy for building a nanoplatform to advance the field of AUTAC in tumor immunotherapy.

3 May 2024 in Journal of Controlled Release
Verified
Journal Article
Closed access
LYLianyi Yang
Lianyi Yang
YWYazhen Wang
Yazhen Wang
Yujun SongYujun Song
Yujun Song
ZLZeya Li
Zeya Li
LLLei Lei
Lei Lei
huile gaohuile gao
huile gao